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Prednisone was shown to induce hyperglycemia in dogs submitted to total 
pancreatectomy and pancreatic islet autotransplantation. The hyperglycemia caused by 
a IO-day course of prednisone, I mg/kg/day, starting on the day of operation was 
reversible within I week after steroid discontinuance. Three weeks after prednisone was 
stopped, there was no detectable adverse effect on glucose homeostasis as judged by 
fasting blood sugar levels and intravenous glucose tolerance test results. Four months 
after transplantation, glucose disappearance was delayed in animals previously treated 
with the prednisone compared with those previously treated with prednisone plus 
insulin or control animals. This was accompanied by lower insulin values on 
intravenous glucose tolerance testing and suggests a long-term subtle effect on islet 
function. The mechanism of the steroid effect is not known. However, this model could 
be used to test the diabetogenicity of other immunosuppressive agents including 
cyclosporine, FK 506, and azathioprine. (SURGERY 7993;773:98-702.) 
From the Transplant Institute, University of Pittsburgh Health Science Center, Pittsburgh, 
Pa., and the Diabetes Research Institute, University of Miami School of Medicine, Miami, Fla. 
SINCE STEROIDS WERE introduced as immunosuppres-
sive agents for clinical renal transplantation, l pred-
nisone has been widely used in many different kinds of 
organ transplants. A steroid diabetogenic effect was 
recognized at the outset. 2 The complication was not 
surprising because it was already known from small 
animal experiments that these agents could induce "ste-
roid diabetes.,,3 Although many subsequent reports 
have emphasized the etiologic role of steroids in post-
transplant diabetes,4-7 Leonard et al. 8 were unable to 
show that prednisone was toxic to human pancreatic is-
lets in vitro or after their transplantation into nude mice. 
The aim of this study was to reexamine this controver-
sial question in an animal model in which the factor of 
rejection was excluded. Delineation of the presence or 
absence of a steroid effect on islet graft function is of 
immediate clinical relevance in view of the resurgence 
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of interest in human islet transplantation for diabetes 
mellitus.9-12 
MATERIAL AND METHODS 
Fourteen adult mongrel dogs weighing 19 to 25 kg 
were randomly divided into three groups. Each dog was 
made diabetic by total pancreatectomy, and the excised 
pancreas was used as the source of islet autografts. Dogs 
in group I (control group; n = 6) were not given pred-
nisone or insulin after islet autotransplantation. Dogs in 
group II (prednisone group; n = 4) were treated with 
prednisone, 1 mg/kg body weight/day (The Upjohn 
Co., Kalamazoo, Mich.), orally for 10 days after islet 
autotransplantation. Dogs in group III (prednisone plus 
insulin; n = 4) were treated with prednisone, 1 mg/kg/ 
day, plus 25 to 30 units/day regular human insulin 
given subcutaneously (Eli Lilly & Co., Indianapolis, 
Ind.) for 10 days after islet autotransplantation. 
The method used for islet isolation was a modifica-
tion of those published previously. 13, 14 The dog's pan-
creatic ducts were cannulated during the pancreatec-
tomy, and 250 ml Hanks' solution containing 1 mg/ml 
collagenase (type p, lot 09; Boehringer Mannheim Bio-
chemicals, Indianapolis, Ind.) was injected. The pan-
creas was then placed in a digestion chamber and sub-
jected to 20 to 25 minutes of enzymatic digestion. 14 The 
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Table I. Description of dog islet grafts 
Group 
N onprednisone 
Mean 
Prednisone 
Mean 
Prednisone + insulin 
Mean 
Dog 
No. 
2 
3 
4 
5 
6 
1 
2 
3 
4 
2 
3 
4 
Body 
weight 
(kg) 
19 
20 
18 
20 
21 
23 
20.17 ± 0.70 
21 
23 
22 
19 
21.25 ± 0.85 
24 
22 
25 
24 
23.75 ± 0.63 
• 'i umber of islets of an avaage size equivalence of ISO units. 
Sex 
F 
F 
M 
F 
F 
M 
F 
F 
M 
M 
M 
M 
F 
M 
separated islets were purified with Euro-Collins Ficoll 
gradients9 (densities were 1.108, 1.096, and 1.037) in a 
cell separator (COBE 2991; Cobe Laboratories, Lake-
wood, Colo.).15,16 The purified islets were cultured 
overnight in CMRL 1066 plus 10% fetal calf serum plus 
penicillin (100 units/ml) plus streptomycin (100 IJ.ID/ 
ml) at 37° C, 95% air, 5% CO2• The islets were injected 
into the portal vein 1 day after pancreatectomy. The is-
let yield expressed as 150 unit size equivalents/kg 
recipient weightl7 was not significantly different in the 
,hree groups. 
Fasting plasma glucose levels were determined in all 
animals with a Beckman glucose analyzer (Beckman 
Instruments, Inc., Fullerton, Calif.) before and daily for 
3 weeks after islet autotransplantation and weekly 
thereafter. An intravenous glucose tolerance test 
(IVGTT) was performed in all animals 3 weeks and 4 
months after transplantation, with 0.5 gm glucose/kg 
body weight. Samples were obtained before and 5, 10, 
30,60,90, and 120 minutes after glucose injection. The 
k value was calculated from the straight line describing 
the change in glucose over time according to the standard 
formula. ls Statistics are presented as mean ± SEM, 
and significance of differences was assessed by Student's 
I test. 
RESULTS 
The mean ( ± SEM) numbers of islets transplanted in 
the three groups were as follows: group I, 12,689 ± 1647 
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Pancreatic 
weight Islet no. Islet/kg 
(gm) (x 7000) * dog weight 
44.5 157.5 8,289.5 
41 284.3 14,215 
39 247.9 13,772.2 
40 387.7 19,385 
38 198.9 9,473 
40 250.2 10,878 
40.5 ± 0.92 254.42 ± 32.2 12,688.78 ± 1646.3 
38 385.3 18,345.2 
43 358.9 15,605.4 
40.2 302.4 13,745.5 
37 299.6 15,768.4 
39.5 ± 1.33 336.55 ± 21.2 15,866.13 ± 945.2 
39.9 357.8 14,908.5 
44.4 368.2 16,736.4 
52 370.2 14,808 
35.2 380.2 10,829.5 
42.88 ± 3.57 369.1 ± 4.59 14,320.6 ± 1245.2 
islets/kg weight; group II, 15,866 ± 945 islets/kg 
weight; and group III, 14,320 ± 1245 islets/kg weight 
(Table I). The daily postoperative fasting blood sugar 
levels for the first 3 postoperative weeks are shown in 
Fig. 1. After islet transplantation, in the untreated con-
trol group, all dogs remained normoglycemic for the 
duration of the study (mean plasma glucose level, 
102 ± 2.5 mg/dl). The dogs treated with prednisonefor 
10 days after islet transplantation were hyperglycemic 
during therapy (mean plasma glucose level, 198 ± 10 
mg/dl). However, the fasting blood sugar levels re-
turned to normal within the first week after the pred-
nisone was stopped (Fig. 1). The dogs treated with 
prednisone plus insulin for 10 days were normoglycemic 
during this time and remained so after discontinuation 
of treatment (mean plasma glucose level, 106 ± 9.8 
mg/dl). Four months after transplantation, fasting 
plasma glucose levels were 119 ± 11 mg/dl in group I, 
123 ± 13 mg/dl in group II, and 123 ± 11 mg/dl in 
group III (data not shown). 
IVGTTs were performed 3 weeks and 4 months af-
ter transplantation. There was no significant difference 
among the groups, although there was a trend for a 
lower k value in group II. Four months after transplan-
tation, fasting plasma glucose levels among the three 
groups were indistinguishable. However, the disap-
pearance rate of intravenously injected glucose was 
slower in group II than in groups I and III (Table II; 
Fig. 2). Insulin values obtained during the 4-month 
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Fig. 1. Weekly fasting plasma glucose levels of (non-prednisone-treated group) control group (n = 6), 
prednisone-treated group (n = 4), and prednisone plus insulin group (n = 4) up to 3 weeks after islet autotrans-
plantation. 
Table II. Plasma glucose levels and k values after islet autotransplantation 
Control 
3 wk 4rno 
FPG (mg/dl) 115 ± 14 119 ± 11 
k Values 2.14 2041 
%/min ±Oo42 ±Oo42 
p < 0.05 compared with control and prednisone plus insulin groups. 
FPC, Fasting plasma glucose. 
IVGTT are shown in Fig. 3. Insulin secretion in all 
groups was similar at the late points on the IVGTT; 
however, at the points before 30 minutes, insulin was 
lower in the prednisone-treated group compared with 
the control and prednisone plus insulin groups. 
DISCUSSION 
In this study we examined the effect of 1 mg/kg 
prednisone on islet autografts in which variables related 
to rejection could be excluded. The amount of pred-
nisone in this study was chosen because of observations 
by Leonard et al. 8 that 1 mg/kg/ day prednisone did not 
inhibit human fetal pancreatic growth in nude mice and 
this dose range is commonly used in whole organ trans-
plantation in humans. 
As expected, 1 mg/kg/day prednisone markedly el-
evated the fasting glucose levels of the islet recipients 
during acute treatment. The effect was reversible on 
discontinuation of prednisone. The IVGTT results 3 
weeks after discontinuation of steroid therapy were not 
significantly different among the groups. Surprisingly, 
Prednisone Prednisone + insulin 
3 wk 4 rno 3 wk 4 rna 
120 ± 24 123 ± 13 99 ± 19 123 ± 11 
1.57 
±O.25 
1.21 * 2.37 2042 
±O.O9 ±Oo4O ±0.35 
4 months after islet autotransplantation, glucose disap-
pearance rate was delayed in the prednisone group 
compared with the control group and prednisone plus 
insulin, group, although fasting glucose levels were nor-
mal in all groups. These results indicated that there was 
a subtle long-term diabetogenic effect of an acute course 
of steroids. Studies performed' in animals with reduced 
B cell mass, or in animals infused chronically with glu-
cose, indicate that hyperglycemia per se can lead to the 
development of B cell unresponsiveness to glucose. 19.21 
This could explain why in our study insulin .treatment 
given acutely prevented steroid-induced hyperglycemia, 
resulting in a long-term beneficial effect on the trans-
planted islets. Although in vitro the effects of high con-
centrations of glucose on islets are rapidly reversible,22 
there is experimental evidence that hyperglycemia 
might irreversibly damage B cells.23 In fact, cats ren-
dered hyperglycemic for 1 month remained diabetic de-
spite discontinuing intraperitoneal glucose administra-
tion, and their islets showed hydropic degeneration.24 
This was also observed in partially pancreatectomized 
I 
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Fig. 2. IVGTT 4 months after islet autotransplantation. 
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Fig. 3. Insulin response to intravenously injected glucose 4 months after islet autotransplantation. 
uogs intravenously infused with glucose. 23 It has been 
;: 'own that chronic hyperglycemia induces metabolic 
adaption rather than degenerative lesions.25 However, 
short-term exposure to high glucose concentrations 
leads normal human islets to a selective insensitivity to 
glucose, which is reversible with restoration of normo-
glycemia.22 Another possibility is that steroids alter 
other islet cell functions, such as glucose transporters, as 
has been shown in peripheral targets for insulin ac-
tion. 26 This would not explain why insulin treatment 
had a beneficial effect in our experiments. Steroid-
induced hyperglycemia is not necessarily caused by a 
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direct effect on islet cell function. It could be explained 
by alterations in hepatic glucose production, peripheral 
glucose disposal, or a combination of these alterations. 5 
Our data indicate some residual effect on islet function. 
Hyperglycemia caused by high-dose steroid therapy for 
a protracted period could adversely affect the islets as 
with Lukens' diabetes.24 
More recently, Kaufman et alY showed that pred-
nisone at a dose of 1 or 2 mg/kg/day had permanent 
toxic effects on canine islet autograft function, as 
evidenced by loss of the islet grafts. One of the possible 
reasons for the disparity between their results and ours 
could be the difference in the mean number of trans-
planted islets. In our study, dogs received 15,867 ± 945 
islets/kg recipient body weight in the prednisone group 
and 14,320 ± 1245 islets/kg in the prednisone plus in-
sulin group. In contrast, in their study, only 7600 ± 
1200 islets/kg were transplanted in prednisone-treated 
animals. This represents a significant (p < 0.05) de-
crease in transplanted B cell mass. Another possible 
difference is the duration of steroid treatment. In our 
studv we examined the potential consequences of short-
term prednisone treatment, whereas the duration of 
steroid treatment was longer in the study of Kaufman 
et al. Nevertheless, we observed impaired insulin secre-
tion and higher glucose levels during IVGTT 4 months 
after islet transplantation in the prednisone-treated an-
imals. This could indicate a potential long-term toxic 
effect of prednisone on islet engraftment or function 
even when a short-course treatment is used. This toxic 
effect appears to be reversed by acute insulin treatment. 
Further long-term studies will be necessary to address 
the issue of mechanisms and reversibility of the steroid 
effect on islet function. This is an important issue in the 
field of islet allotransplantation because steroids repre-
sent the dose-maneuverable component of multiple drug 
regimens that are used to prevent or reverse graft rejec-
tion in the early postoperative period. 
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